Telmisartan as a metabolic sartan: The first meta-analysis of randomized controlled trials in metabolic syndrome

Journal of the American Society of Hypertension

Volumn 7, Issue 3, 2013, Pages 229-235

  Takagi, Hisato ^a   Niwa, Masao ^a   Mizuno, Yusuke ^a   Goto, Shin Nosuke ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Meta analysis; metabolic syndrome; randomized controlled trial; telmisartan

Indexed keywords

CANDESARTAN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; IRBESARTAN; LOSARTAN; ROSIGLITAZONE; TELMISARTAN; VALSARTAN;

ARTICLE; DATA BASE; DIET RESTRICTION; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; INFORMATION PROCESSING; META ANALYSIS; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; HUMANS; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876665870     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2013.02.006     Document Type: Article

References (38)

1. A.J. Scheen Management of the metabolic syndrome Minerva Endocrinol 29 2004 31 45
2. J.R. Sowers, and E.D. Frohlich Insulin and insulin resistance: Impact on blood pressure and cardiovascular disease Med Clin North Am 88 2004 63 82 (Pubitemid 38165387)
3. S. Yamagishi, and M. Takeuchi Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property Med Hypotheses 64 2005 476 478 (Pubitemid 40023005)
4. J.P. Higgins, J.J. Deeks, and D.G. Altman Chapter 16: Special topics in statistics J.P. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011 The Cochrane Collaboration Copenhagen, Denmark Available from: www.cochrane-handbook.org
5. K. Murakami, J. Wada, D. Ogawa, C.S. Horiguchi, T. Miyoshi, and M. Sasaki The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO) Diab Vasc Dis Res 10 May 2013 93 96
6. O. Bahadir, M. Uzunlulu, A. Oguz, and M.A. Bahadir Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome Hypertens Res 30 2007 49 53
7. I.N. Bähr, P. Tretter, J. Krüger, R.G. Stark, J. Schimkus, and T. Unger High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome Hypertension 58 2011 725 732
8. G. Derosa, A.F. Cicero, A. D'Angelo, P.D. Ragonesi, L. Ciccarelli, and M.N. Piccinni Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-alpha Hypertens Res 29 2006 849 856 (Pubitemid 46062116)
9. Y. Ichikawa Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome Intern Med 46 2007 1331 1336 (Pubitemid 47455754)
10. T. Kishi, Y. Hirooka, S. Konno, and K. Sunagawa Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome J Hypertens 30 2012 1646 1655
11. M. Shimabukuro, H. Tanaka, and T. Shimabukuro Effects of telmisartan on fat distribution in individuals with the metabolic syndrome J Hypertens 25 2007 841 848 (Pubitemid 46398879)
12. C. Vitale, G. Mercuro, C. Castiglioni, A. Cornoldi, A. Tulli, and M. Fini Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome Cardiovasc Diabetol 4 2005 6
13. P. Wohl, E. Krusinová, M. Hill, S. Kratochvílová, K. Zídková, and J. Kopecký Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose Eur J Endocrinol 163 2010 573 583
14. Y. Yano, S. Hoshide, J. Ishikawa, C. Noguchi, D. Tukui, and H. Takanori The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients Am J Hypertens 20 2007 565 572 (Pubitemid 46691290)
15. G.L. Xi, J.W. Cheng, and G.C. Lu Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension Am J Hypertens 21 2008 546 552
16. Z. Zheng, S. Lin, and H. Shi A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension J Clin Hypertens (Greenwich) 12 2010 414 421
17. J.P. Baguet, B. Legallicier, P. Auquier, and S. Robitail Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure Clin Drug Investig 27 2007 735 753 (Pubitemid 47529290)
18. H. Takagi, Y. Mizuno, S.N. Goto, T. Umemoto ALICE (All-Literature Investigation of Cardiovascular Evidence) Group Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: A meta-analysis of head-to-head randomized trials e-pub ahead of print Int J Cardiol 5 Dec 2012 pii: S0167-5273(12)01569-0. doi: 10.1016/j.ijcard.2012.11.086
19. F. Ziemke, and C.S. Mantzoros Adiponectin in insulin resistance: Lessons from translational research Am J Clin Nutr 91 2010 258S 261S
20. S. Li, H.J. Shin, E.L. Ding, and R.M. van Dam Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis JAMA 302 2009 179 188
21. M.B. Schulze, I. Shai, E.B. Rimm, T. Li, N. Rifai, and F.B. Hu Adiponectin and future coronary heart disease events among men with type 2 diabetes Diabetes 54 2005 534 539
22. H. Chen, M. Montagnani, T. Funahashi, I. Shimomura, and M.J. Quon Adiponectin stimulates production of nitric oxide in vascular endothelial cells J Biol Chem 278 2003 45021 45026 (Pubitemid 37377262)
23. Y. Arita, S. Kihara, N. Ouchi, K. Maeda, H. Kuriyama, and Y. Okamoto Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell Circulation 105 2002 2893 2898 (Pubitemid 34666104)
24. T.P. Combs, J.A. Wagner, J. Berger, T. Doebber, W.J. Wang, and B.B. Zhang Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: A potential mechanism of insulin sensitization Endocrinology 143 2002 998 1007 (Pubitemid 34164048)
25. N. Maeda, M. Takahashi, T. Funahashi, S. Kihara, H. Nishizawa, and K. Kishida PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2001 2094 2099 (Pubitemid 33643677)
26. S. Yamagishi, K. Nakamura, and T. Matsui Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders Curr Mol Med 7 2007 463 469 (Pubitemid 47244891)
27. T.W. Kurtz Treating the metabolic syndrome: Telmisartan as a peroxisome proliferator-activated receptor-gamma activator Acta Diabetol 42 Suppl 1 2005 S9 16
28. H. Takagi, and T. Umemoto Telmisartan increases adiponectin levels: A meta-analysis and meta-regression of randomized head-to-head trials Int J Cardiol 155 2012 448 451
29. S. Genuth, K.G. Alberti, P. Bennett, J. Buse, R. Defronzo, and R. Kahn Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 2003 3160 3167 (Pubitemid 37339514)
30. American Diabetes Association Clinical Practice Recommendations 2005 Diabetes Care 28 Suppl 1 2005 S1 S79
31. D.B. Sacks, D.E. Bruns, D.E. Goldstein, N.K. Maclaren, J.M. McDonald, and M. Parrott Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Clin Chem 48 2002 436 472 (Pubitemid 34174577)
32. H.J. Woerle, W.P. Pimenta, C. Meyer, N.R. Gosmanov, E. Szoke, and T. Szombathy Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values Arch Intern Med 164 2004 1627 1632 (Pubitemid 39037941)
33. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495 (Pubitemid 38680001)
34. E. Bonora, G. Targher, M. Alberiche, R.C. Bonadonna, F. Saggiani, and M.B. Zenere Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity Diabetes Care 23 2000 57 63 (Pubitemid 30022895)
35. S.M. Haffner, E. Kennedy, C. Gonzalez, M.P. Stern, and H. Miettinen A prospective analysis of the HOMA model. The Mexico City Diabetes Study Diabetes Care 19 1996 1138 1141 (Pubitemid 26334266)
36. H. Takagi, and T. Umemoto Telmisartan improves insulin sensitivity: A meta-analysis of randomized head-to-head trials Int J Cardiol 156 2012 92 96
37. S. Yusuf, H.C. Diener, R.L. Sacco, D. Cotton, S. Ounpuu, and W.A. Lawton Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 2008 1225 1237
38. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial Lancet 372 2008 1174 1183 Erratum in: Lancet 2008;372:1384